Real-life treatment of cholinergic urticaria with omalizumab

Slides:

Advertisements

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Advertisements

Severe adult-onset asthma: A distinct phenotype

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

The natural history of soy allergy

Allergen immunotherapy: A practice parameter third update

Risk of an asthma exacerbation after bariatric surgery in adults

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Responsiveness and minimal important difference of the urticaria control test Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria Ragip Ertas, MD, Kemal Ozyurt,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study Karoline Krause, MD, Athanasios Tsianakas,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

David A. Khan, MD Journal of Allergy and Clinical Immunology

Shyam Joshi, MD, David A. Khan, MD

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Pavel Kolkhir, MD, Martin K

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Stanley J. Szefler, MD, Richard J. Martin, MD

Rising prevalence of asthma is sex-specific in a US farming population

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase Marcus Maurer, MD, Sabine Altrichter, MD,

The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria Tse Wen Chang, PhD, Christina Chen, BS, Chien-Jen.

Clinical characteristics and genotype-phenotype correlations in C3 deficiency Yuka Okura, MD, PhD, Ichiro Kobayashi, MD, PhD, Masafumi Yamada, MD, PhD,

Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions Maria José Torres, MD, PhD,

A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Jon Genuneit, MD, MSc Journal of Allergy and Clinical Immunology

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Update on the role of prostaglandins in allergic lung inflammation: Separating friends from foes, harder than you might think Martin L. Moore, PhD, R.

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

Jeffrey M. Harris, MD, PhD, Christopher R

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria Janine Gericke, PhD, Martin Metz, MD, Tatevik Ohanyan,

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

New pathways for itching in patients with atopic dermatitis?

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria Katja Koch, Karsten Weller, MD, Andreas Werner,

Risk of oral food challenges

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

Partial improvement of solar urticaria after omalizumab

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Pedro Giavina-Bianchi, MD, PhD, Shih-Wen Huang, MD

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria Maria Staevska, MD, Todor A.

Advances in pediatric asthma in 2007

Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts Helen Chapel, MA,

Natural history of cow’s milk allergy

The Editors’ Choice Journal of Allergy and Clinical Immunology

Primary prevention of asthma and allergy

Presentation transcript:

Real-life treatment of cholinergic urticaria with omalizumab Sabine Altrichter, MD, Mati Chuamanochan, MD, Henriette Knoth, Aida Asady, MD, Tatevik Ohanyan, MD, Martin Metz, MD, Marcus Maurer, MD Journal of Allergy and Clinical Immunology Volume 143, Issue 2, Pages 788-791.e8 (February 2019) DOI: 10.1016/j.jaci.2018.08.050 Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 A, Response rate to the final dose of omalizumab in patients with CholU (n = 16). B, Timeline and the clinical response of 6 patients who received omalizumab updosing. The dosing and intervals (in weeks) of individual treatment are shown in the squares. *Patient achieved complete response initially and became a major responder later. Journal of Allergy and Clinical Immunology 2019 143, 788-791.e8DOI: (10.1016/j.jaci.2018.08.050) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Response rate to the standard dose of omalizumab (300 mg every 4 weeks) in patients with CholU (n = 15). Response groups are depicted in different colors. Numbers give the percentage of patients in the various response groups. Journal of Allergy and Clinical Immunology 2019 143, 788-791.e8DOI: (10.1016/j.jaci.2018.08.050) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E2 Display of response rates to the final omalizumab dose, separated by sex. Response groups are depicted in different colors. CR, Complete response; MR, major response; NR, no response; PR, partial response. Journal of Allergy and Clinical Immunology 2019 143, 788-791.e8DOI: (10.1016/j.jaci.2018.08.050) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E3 A-D, Correlation of the clinical response to the final omalizumab dose and patient age (Fig E3, A), age at onset (Fig E3, B), duration of disease (Fig E3, C), and total IgE level (Fig E3, D). None of the response groups were significantly different in any figure. CR, Complete response; MR, major response; NR, no response; PR, partial response. Journal of Allergy and Clinical Immunology 2019 143, 788-791.e8DOI: (10.1016/j.jaci.2018.08.050) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions